Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Is FFR-Guided Strategy Still Valuable?

Doosup Shin; Tae-Min Rhee; Seung Hun Lee; Joo Myung Lee

doi:10.4070/kcj.2021.0416

Journal List > Korean Circ J > v.52(4) > 1162081

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Shin, Rhee, Lee, and Lee: Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Is FFR-Guided Strategy Still Valuable?

Perspectives for Outbreaking Issues

Korean Circulation Journal 2022; 52(4): 280-287.

Published online: 21 March 2022

DOI: https://doi.org/10.4070/kcj.2021.0416

Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Is FFR-Guided Strategy Still Valuable?

Doosup Shin, MD^1,^*

, Tae-Min Rhee, MD^2,^*

, Seung Hun Lee, MD, PhD³

, Joo Myung Lee, MD, MPH, PhD⁴

¹Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

²Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.

³Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.

⁴Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence to Joo Myung Lee, MD, MPH, PhD. Department of Internal Medicine and Cardiovascular Center, Heart Vascular Stroke Institute, Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Korea. drone80@hanmail.net, joomyung.lee@samsung.com

Equal contributor:

^*Doosup Shin and Tae-Min Rhee contributed equally to this work.

Received 20 December 2021 Revised 16 February 2022 Accepted 10 March 2022

The Korean Society of Cardiology

https://creativecommons.org/licenses/by-nc/4.0/

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author's summary

Several randomized clinical trials (RCTs) have shown the benefit of complete revascularization (CR) over culprit-only percutaneous coronary intervention (PCI) in ST-segment elevated myocardial infarction (STEMI) patients with multivessel disease (MVD). Nevertheless, optimal strategy to select targets for non-culprit PCI has not been clarified. Revascularization of the non-culprit lesions can be performed based on either angiographic severity or fractional flow reserved. There exists a paucity of evidence as to which strategy is better when selecting the targets for non-culprit PCI. We critically discuss and compare the safety and efficacy of different strategies for CR in patients with STEMI and MVD using a Bayesian network meta-analysis including all previous RCTs.

Abstract

Several studies have shown the benefit of complete revascularization (CR) over culprit-only percutaneous coronary intervention (PCI) in patients with ST-segment elevated myocardial infarction (STEMI) and multivessel disease (MVD). Nevertheless, optimal strategy to select targets for non-culprit PCI has not been clarified. In this paper, we critically discuss and compare the safety and efficacy of different strategies for CR in patients with STEMI and MVD using a Bayesian network meta-analysis including all previous randomized controlled trials (RCTs). In Bayesian network meta-analysis of 13 RCTs, culprit-only PCI was associated with higher risk of major adverse cardiac events (MACE), compared with angiography-guided or fractional flow reserve (FFR)-guided CR strategies. However, there was no significant difference between angiography-guided and FFR-guided CR strategies in the risk of MACE and its individual components including all-cause death, cardiac death, myocardial infarction (MI), and revascularization. These evidence support that both angiography-guided and FFR-guided complete revascularization strategies would be reasonable treatment option in patients with STEMI and MVD. If the non-culprit lesion is severe on visual assessment, angiography-guided PCI can be considered. If the non-culprit lesion is intermediate in severity or unclear based on visual assessment, FFR-guided strategy can be used as a reliable and objective tool, providing similar benefits with less stents compared with an angiography-guided strategy. Further RCT is needed to evaluate direct comparison between angiography-guided and FFR-guided CR strategies in patients with STEMI and MVD. Ongoing FRAME-AMI trial (NCT02715518) will provide more evidence regarding this issue.

Keywords: Acute myocardial infarction, Percutaneous coronary intervention, ST-segment elevation myocardial infarction, Fractional flow reserve, Meta-analysis

INTRODUCTION

Nearly half of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel disease (MVD) with significant stenoses in non-culprit vessels, and these patients showed higher risks of death or re-infarction after primary percutaneous coronary intervention (PCI). Achieving complete revascularization (CR) through multivessel PCI in these patients may not only reduce the risk of repeat revascularization but may also improve clinical outcomes by promoting recovery of myocardial perfusion. Indeed, several randomized clinical trials (RCTs) have shown the benefit of CR over culprit-only PCI in patients with STEMI1)2)3)4) and guidelines recommend multivessel PCI in STEMI patients.

Nevertheless, optimal strategy to select targets for non-culprit PCI has not been clarified. Revascularization of the non-culprit lesions can be performed based on either 1) angiographic severity assessed by diameter stenosis (DS) on visual estimation or quantitative coronary angiography, or 2) functional significance assessed by invasive physiologic indices, such as fractional flow reserve (FFR). While previous trials focused on the comparison between CR and culprit-only PCI, there exists a paucity of evidence as to which strategy is better when selecting the targets for non-culprit PCI. Although recent FLOWER-MI trial compared those 2 strategies,5) the results were inconclusive and several issues still remain. In this paper, we critically discuss and compare the safety and efficacy of different strategies for CR in patients with STEMI and MVD using a Bayesian network meta-analysis including all previous RCTs.1)2)3)4)5)6)7)8)9)10)11)12)13)14)15)16)

COMPLETE VERSUS CULPRIT-ONLY REVASCULARIZATION IN ST-SEGMENT ELEVATED MYOCARDIAL INFARCTION

Multiple RCTs have evaluated the role of CR in patients with STEMI and MVD (Table 1). In PRAMI trial, 465 patients with STEMI were randomly assigned into preventive PCI (CR) or no preventive PCI (culprit-only) groups.10) Patients assigned to the preventive PCI group underwent angiography-guided PCI of all non-culprit lesions with DS ≥50% during the index procedure. During a mean follow-up of 23 months, CR significantly reduced the primary outcome, a composite of cardiac death, nonfatal MI, or refractory angina (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.21–0.58; p<0.001).10) More recently, COMPLETE trial, by far the largest clinical trial on this topic, also showed the benefit of CR in STEMI patients.1) At a median follow-up of 3 years, the risk of composite of cardiovascular death or MI was significantly lower in the preventive PCI group compared with the culprit-only PCI group (HR, 0.74; 95% CI, 0.60–0.91; p=0.004).1) Thus, the above studies demonstrated that CR not only reduced the risk of repeat revascularization but also improved hard outcomes, supporting the importance of achieving CR in patients with STEMI and MVD.

Table 1

Characteristics of included studies

Study (years)		Enroll period	CR strategy	CR timing	No. of patients		Primary outcome	Follow-up duration	Non-culprit lesion criteria	Baseline characteristics of individual studies
Study (years)		Enroll period	CR strategy	CR timing	CR	Culprit-only	Primary outcome	Follow-up duration	Non-culprit lesion criteria	Age (years)	DM (%)	3-VD (%)	Anterior MI (%)	EF (%)
Angiography-guided CR vs. culprit-only
	HELP-AMI (2004)6)	NR	Angio-guided	Immediate	52	17	Any death, MI, RR	12 months	NR	63.5/65.3	11.5/41.2	30.8/47.1	51.9/58.8	48.4/48.9
	Politi et al. (2006)8)	2003–2007	Angio-guided	Staged or immediate (1:1)	130	84	Any death, MI, ACS admission, RR	Mean 30 months	>70% DS	64.3/66.5	16.1/23.8	36.9/25.0	45.8/41.7	45.2/44.6
	PRAMI (2013)10)	2008–2013	Angio-guided	Immediate	234	231	Cardiac death, MI, refractory angina	Median 23 months	≥50% DS	62/62	15/21	39/33	29/39	NR
	PRAGUE-13 (2015)12)	2009–2013	Angio-guided	Staged	106	108	Any death, MI, stroke	Median 38 months	≥70% DS with ≥2.5 mm diameter	65.0/65.2	27/30	NR	39/30	45.8/48.0
	Zhang et al. (2015)13)	2009–2012	Angio-guided	Staged	215	213	Cardia death, MI	24 months	75–90% DS with ≥2.5 mm diameter	62.3/61.9	36.7/35.2	NR	36.7/39.9	58.8/57.9
	Hamza et al. (2016)14)	2013–2014	Angio-guided	Immediate or staged	50	50	Any death, MI, ID-RR	Up to 6 months	≥80% DS (50–70% excluded)	56.4/52.2	100/100	28/34	48/46	45.9/46.8
	CvLPRIT (2015, 2019)2)11)	2011–2013	Angio-guided	Immediate (64.7%)	150	146	Any death, MI, HF, ID-RR	Median 67.2 months	>70% single view or >50% 2 views	64.6/65.3	12.9/14.3	20.7/24.7	36.0/35.6	45.8/45.1
	CvLPRIT (2015, 2019)2)11)	2011–2013	Angio-guided	Immediate (64.7%)	150	146	Any death, MI, HF, ID-RR	Median 67.2 months	≥2 mm diameter	64.6/65.3	12.9/14.3	20.7/24.7	36.0/35.6	45.8/45.1
	CROSS-AMI (2019)17)	2010–2015	Angio-guided	Staged	154	152	Cardiac death, MI, RR, HF re-admission	31 months	≥50% DS (QCA) or ≥70% DS (visual)	62/62	14/15	42/45	36/36	59/57
	COMPLETE (2019)1)	2013–2017	Angio-guided	Staged	2,016	2,025	Cardiac death, MI, or ID-RR	Median 36 months	≥70% DS (visual)	61.6/62.4	19.1/19.9	NR	34.6/34.1	NR
									50–69% DS with FFR ≤0.80 (<1%)
									≥2.5 mm diameter
FFR-guided CR vs. culprit-only
	Ghani and Dambrink (2010, 2012)7)9)	2004–2007	FFR-guided	Staged	79	40	Any death, MI, RR	36 months	≥50% DS with ≥2.5 mm diameter	62/61	6.3/5.0	25.0/19.5	21.3/29.3	58.9/55.9
	Ghani and Dambrink (2010, 2012)7)9)	2004–2007	FFR-guided	Staged	79	40	Any death, MI, RR	36 months	CR for FFR <0.75 or DS >90%	62/61	6.3/5.0	25.0/19.5	21.3/29.3	58.9/55.9
	DANAMI-3-PRIMULTI (2016)4)	2011–2014	FFR-guided	Staged	314	313	Any death, MI, non-culprit ID-RR	Median 27 months	>50% DS with ≥2 mm diameter	64/63	9/13	31/32	33/36	50/50
	DANAMI-3-PRIMULTI (2016)4)	2011–2014	FFR-guided	Staged	314	313	Any death, MI, non-culprit ID-RR	Median 27 months	CR for FFR ≤0.80 or DS >90%	64/63	9/13	31/32	33/36	50/50
	COMPARE-ACUTE (2017, 2020)3)16)	2011–2015	FFR-guided	Immediate (83.4%)	295	590	Any death, MI, RR, CVA	36 months	≥50% DS with ≥2 mm diameter	62/61	14.6/15.9	30.8/32.9	35.6/34.9	NR
	COMPARE-ACUTE (2017, 2020)3)16)	2011–2015	FFR-guided	Immediate (83.4%)	295	590	Any death, MI, RR, CVA	36 months	CR for FFR ≤0.80	62/61	14.6/15.9	30.8/32.9	35.6/34.9	NR
FFR-guided CR vs. angiography-guided CR
	FLOWER-MI (2021)5)	2016–2018	FFR- versus angio-guided	Staged (96%)	FFR-guided: 586		Any death, MI, urgent RR	12 months	≥50% DS with ≥2 mm diameter	62.5/61.9	18.3/14.2	25.9/20.1	29.8/34.6	50/50
	FLOWER-MI (2021)5)	2016–2018	FFR- versus angio-guided	Staged (96%)	Angio-guided: 577		Any death, MI, urgent RR	12 months	CR for FFR ≤0.80 in FFR-guided group	62.5/61.9	18.3/14.2	25.9/20.1	29.8/34.6	50/50

CR = complete revascularization; CVA = cerebrovascular accident; DM = diabetes mellitus; DS = diameter stenosis; EF = ejection fraction; FFR = fractional flow reserve; HF = heart failure; ID-RR = ischemia-driven repeat revascularization; MI = myocardial infarction; NR = not reported; QCA = quantitative coronary angiography; RR = repeat revascularization; STEMI = ST-segment elevation myocardial infarction; 3-VD = 3-vessel disease.

SELECTION OF NON-CULPRIT LESIONS FOR COMPLETE REVASCULARIZATION

Although CR has clearly been shown to be beneficial in patients with STEMI, clinical trials have used different criteria to select targets for non-culprit PCI (Table 1). In most studies, non-culprit lesions were assessed angiographically, and PCI was performed based on the angiographic lesion severity with a cutoff DS of 50% to 70%. In COMPLETE trial, CR was achieved by revascularizing non-culprit lesions with DS of ≥70% on visual assessment or 50–69% with positive FFR ≤0.80.1) However, less than 1% of the lesions were assessed by FFR. In fact, all the benefits of non-culprit PCI were observed among lesions with DS of ≥80% by visual assessment (≥60% on laboratory assessment).1) These results support the usefulness of an angiography-guided non-culprit PCI, especially when the degree of stenosis is clearly severe on visual assessment.

However, it should also be noted that the angiographic severity of non-culprit lesions can be overestimated in the acute phase of MI, which could lead to stenting hemodynamically nonsignificant lesions. In this regard, feasibility and usefulness of physiology-guided PCI have been studied in patients with acute coronary syndrome. In patients with STEMI, DANAMI-3-PRIMULTI and COMPARE-ACUTE trials consistently showed significantly better clinical outcome following FFR-guided CR compared with culprit-only PCI.3)4) These outcome trials support that FFR-guided PCI is also beneficial in patients with MI, and FFR-guided CR is an effective strategy in patients with STEMI and MVD.

PHYSIOLOGY- VERSUS ANGIOGRAPHY-GUIDED REVASCULARIZATION OF THE NON-INFARCT-RELATED ARTERIES

Although both angiography-guided and FFR-guided non-culprit PCI have been proven to be beneficial in patients with STEMI, there has been lack of evidence as to which strategy is better in this population. Recently published FLOWER-MI was the first RCT which directly compared angiography-guided versus FFR-guided CR in patients with STEMI and MVD.5) In this study, 577 and 586 patients were randomly assigned to angiography-guided or FFR-guided strategies, respectively. During 1-year follow up, there was no significant difference between the 2 strategies in primary outcome, a composite of death, MI, and urgent revascularization (HR, 1.32; 95% CI, 0.78–2.23; p=0.31). Authors noticed that the event-rate curves for the primary outcome diverged after 6 months and hypothesized that the untreated non-culprit lesions in the FFR-guided group could have worsened during the follow-up.

However, the results of this trial need to be interpreted with caution. First, the incidence of periprocedural MI, which was part of the primary outcome, was significantly higher in FFR-guided PCI group (7 out of 18 nonfatal MIs in FFR-guided group versus 2 out of 10 nonfatal MIs in angiography-guided group). Considering that the angiography-guided strategy resulted in more interventions, higher incidence of periprocedural MIs in FFR-guided group could be an artifact, thereby contributing to the numerical difference in the primary outcome. Second, 7 out of 9 deaths occurring in the FFR-guided group were due to non-cardiac etiologies (e.g., cancer, end-stage renal disease, post-trauma hemorrhage, or acute pancreatitis) and only 2 deaths were cardiac related, whereas 7 out of 10 deaths occurring in the angiography-guided group were cardiac related. Third, although failure rates of the non-culprit PCI were reported to be same in both groups (4.7% for each), 5 non-culprit PCIs in FFR-guided group resulted in post-procedure thrombolysis in myocardial infarction (TIMI) flow of 0, whereas none in angiography-guided group had post-procedure TIMI flow of 0. Fourth, 15.7% of interrogated lesions had missing FFR value, suggesting lack of core laboratory validation of FFR values in the trial. These facts raise concerns regarding the reliability of results of this trial. Despite these concerns being unfavorable to the FFR-guided strategy, there was no significant difference in clinical outcomes between the 2 strategies, and significantly less PCI and stents were required in the FFR-guided strategy.

To further investigate this topic, we performed a network meta-analysis using the Bayesian extension of the hierarchical random-effects model to extract indirect comparison results in pairs. As shown in Figure 1, both angiography-guided and FFR-guided CR strategies were associated with lower risks of cardiac death and MACE compared with culprit-only PCI strategy. There was no significant difference between angiography-guided and FFR-guided CR strategies in the risk of all-cause death, cardiac death, MI, revascularization, and MACE. In sensitivity analysis, non-significant trend of MI favoring angiography-guided CR was mostly affected by the results of a small trial which compared FFR-guided CR with culprit-only PCI.7)9) In studies of Dambrink et al.7) and Ghani et al.,9) there were significantly more deaths (5.1% vs. 0%) and MIs (17.7% vs. 0%) in the FFR-guided CR group than the culprit-only PCI group,9) which were not seen in more recent, larger trials.3)4) This suggests that the results of the trial could have been biased. Furthermore, heterogeneous definitions of MI (especially, periprocedural MI) among the studies were major sources of bias in interpreting comparative prognosis between angiography-guided and FFR-guided strategies. Nevertheless, the overall results of the current network meta-analysis emphasize the importance of CR in patients with STEMI and MVD, regardless of the strategy for non-culprit PCI.

Figure 1

Network meta-analysis comparing culprit-only PCI, FFR-guided, and angiography-guided CR.

(A-F) Results from network meta-analysis using the Bayesian extension of the hierarchical random-effects model are presented.

ACS = acute coronary syndrome; Angio-CR = angiography-guided complete revascularization; Culprit-only = culprit-only percutaneous coronary intervention; CR = complete revascularization; CrI = credible interval; CVA = cerebrovascular accident; DM = diabetes mellitus; DS = diameter stenosis; EF = ejection fraction; FFR = fractional flow reserve; FFR-CR = fractional flow reserve-guided complete revascularization; HF = heart failure; ID = ischemia-driven; MI = myocardial infarction; NR = not reported; QCA = quantitative coronary angiography; RR = repeat revascularization; VD = vessel disease.

FUTURE PERSPECTIVES

We discussed the importance of CR in patients with STEMI and compared different strategies to select targets for non-culprit PCI. Based on the results of available trials and the present network meta-analysis, both angiography-guided and FFR-guided CR would provide similar benefits over culprit-only PCI in patients with STEMI and MVD. Considering the benefit of angiography-guided CR was mostly seen among non-culprit lesions with DS of ≥80% on visual assessment,1) and that FFR would be concordant in most of those lesions, it may be reasonable to consider revascularization of such severe lesions without further tests. If the non-culprit lesions are intermediate in severity or unclear based on visual assessment, FFR-guided strategy can be used as a reliable and objective tool to select targets for non-culprit PCI, providing similar benefits with less stents compared with an angiography-guided strategy. In addition, comparable outcomes between the 2 strategies allow the operators to choose one strategy over the other based on various factors, such as operator experience, availability of physiologic assessment, and overall cost, until more data become available. It should be noted that there has been very limited evidence regarding the direct comparison between angiography-guided and FFR-guided strategies. Therefore, the results from the current network meta-analysis should be regarded as hypothesis generating.

Ongoing FRAME-AMI (NCT02715518) trial which directly compare angiography-guided and FFR-guided strategies will provide more insight into the optimal CR strategy in patients with STEMI and MVD. Another interesting question is whether preventive PCI of non-culprit lesions, according to the intravascular imaging-based vulnerability would prevent future events. The concept of vulnerability-guided PCI has not yet been proven to be beneficial in this population. Future studies such as the OCT CONTACT trial (NCT04878133) will test this concept.

CONCLUSIONS

In Bayesian network meta-analysis of 13 RCTs, both angiography-guided and FFR-guided CR strategies showed significantly lower risk of MACE than culprit-only PCI in patients with STEMI and MVD. However, there was no significant difference between angiography-guided and FFR-guided CR strategies in the risk of MACE and its individual components including all-cause death, cardiac death, MI, and revascularization. Further RCT is needed to evaluate direct comparison between angiography-guided and FFR-guided CR strategies in patients with STEMI and MVD.

Notes

Funding: Dr. Joo Myung Lee received a Research Grant from St. Jude Medical (Abbott Vascular) and Philips Volcano.

Conflict of Interest: The authors have no financial conflicts of interest.

Data Sharing Statement: The data generated in this study is available from the corresponding author(s) upon reasonable request.

Author Contributions:

Conceptualization: Shin D, Rhee TM, Lee SH, Lee JM.
Data curation: Shin D, Rhee TM, Lee JM.
Formal analysis: Shin D, Rhee TM, Lee JM.
Funding acquisition: Lee JM.
Investigation: Shin D, Lee SH, Lee JM.
Methodology: Shin D, Rhee TM, Lee SH, Lee JM.
Project administration: Shin D, Lee JM.
Resources: Rhee TM, Lee JM.
Software: Shin D, Rhee TM, Lee JM.
Supervision: Shin D, Rhee TM, Lee JM.
Validation: Shin D, Rhee TM, Lee JM.
Visualization: Shin D, Rhee TM, Lee JM.
Writing - original draft: Shin D, Rhee TM, Lee SH, Lee JM.
Writing - review & editing: Shin D, Rhee TM, Lee SH, Lee JM.

References

1. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019; 381:1411–1421. PMID: 31475795.

2. Gershlick AH, Banning AS, Parker E, et al. Long-term follow-up of complete versus lesion-only revascularization in STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2019; 74:3083–3094. PMID: 31856964.

3. Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017; 376:1234–1244. PMID: 28317428.

4. Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015; 386:665–671. PMID: 26347918.

5. Puymirat E, Cayla G, Simon T, et al. Multivessel PCI Guided by FFR or angiography for myocardial infarction. N Engl J Med. 2021; 385:297–308. PMID: 33999545.

6. Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) study. Int J Cardiovasc Intervent. 2004; 6:128–133. PMID: 16146905.

7. Dambrink JH, Debrauwere JP, van ’t Hof AW, et al. Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines? EuroIntervention. 2010; 5:968–975. PMID: 20542783.

8. Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart. 2010; 96:662–667. PMID: 19778920.

9. Ghani A, Dambrink JH, van ’t Hof AW, Ottervanger JP, Gosselink AT, Hoorntje JC. Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial. Neth Heart J. 2012; 20:347–353. PMID: 22622701.

10. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013; 369:1115–1123. PMID: 23991625.

11. Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015; 65:963–972. PMID: 25766941.

12. Hlinomaz AO, Groch L, Poloková K, et al. Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularisation versus conservative strategy. Prague-13 trial. Kardiol Rev Int Med. 2015; 17:214–220.

13. Zhang J, Wang Q, Yang H, et al. Evaluation of different revascularization strategies for patients with acute myocardial infarction with lesions of multiple coronary arteries after primary percutaneous coronary intervention and its economic evaluation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015; 27:169–174. PMID: 25757964.

14. Hamza M, Mahmoud N, Elgendy IY. A randomized trial of complete versus culprit-only revascularization during primary percutaneous coronary intervention in diabetic patients with acute ST elevation myocardial infarction and multi vessel disease. J Interv Cardiol. 2016; 29:241–247. PMID: 27245121.

15. Calviño-Santos R, Estévez-Loureiro R, Peteiro-Vázquez J, et al. Angiographically guided complete revascularization versus selective stress echocardiography-guided revascularization in patients with ST-segment-elevation myocardial infarction and multivessel disease: the CROSS-AMI randomized clinical trial. Circ Cardiovasc Interv. 2019; 12:e007924. PMID: 31554422.

16. Smits PC, Laforgia PL, Abdel-Wahab M, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial. EuroIntervention. 2020; 16:225–232. PMID: 32250250.

17. Calviño-Santos R, Estévez-Loureiro R, Peteiro-Vázquez J, et al. Angiographically guided complete revascularization versus selective stress echocardiography-guided revascularization in patients with ST-segment-elevation myocardial infarction and multivessel disease: the CROSS-AMI randomized clinical trial. Circ Cardiovasc Interv. 2019; 12:e007924. PMID: 31554422.

TOOLS

Similar articles